202 related articles for article (PubMed ID: 29246438)
21. High-Generation Amphiphilic Janus-Dendrimers as Stabilizing Agents for Drug Suspensions.
Selin M; Nummelin S; Deleu J; Ropponen J; Viitala T; Lahtinen M; Koivisto J; Hirvonen J; Peltonen L; Kostiainen MA; Bimbo LM
Biomacromolecules; 2018 Oct; 19(10):3983-3993. PubMed ID: 30207704
[TBL] [Abstract][Full Text] [Related]
22. Clarification of the Dissolution Mechanism of an Indomethacin/Saccharin/Polyvinylpyrrolidone Ternary Solid Dispersion by NMR Spectroscopy.
Kosaka M; Higashi K; Nishimura M; Ueda K; Moribe K
J Pharm Sci; 2020 Dec; 109(12):3617-3624. PubMed ID: 32931779
[TBL] [Abstract][Full Text] [Related]
23. Increased dissolution and oral absorption of itraconazole/Soluplus extrudate compared with itraconazole nanosuspension.
Zhang K; Yu H; Luo Q; Yang S; Lin X; Zhang Y; Tian B; Tang X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1285-92. PubMed ID: 23562534
[TBL] [Abstract][Full Text] [Related]
24. Investigation of properties and recrystallisation behaviour of amorphous indomethacin samples prepared by different methods.
Karmwar P; Graeser K; Gordon KC; Strachan CJ; Rades T
Int J Pharm; 2011 Sep; 417(1-2):94-100. PubMed ID: 21182910
[TBL] [Abstract][Full Text] [Related]
25. Effect of processing route on the surface properties of amorphous indomethacin measured by inverse gas chromatography.
Burnett DJ; Khoo J; Naderi M; Heng JY; Wang GD; Thielmann F
AAPS PharmSciTech; 2012 Dec; 13(4):1511-7. PubMed ID: 23135965
[TBL] [Abstract][Full Text] [Related]
26. Better understanding of dissolution behaviour of amorphous drugs by in situ solid-state analysis using Raman spectroscopy.
Savolainen M; Kogermann K; Heinz A; Aaltonen J; Peltonen L; Strachan C; Yliruusi J
Eur J Pharm Biopharm; 2009 Jan; 71(1):71-9. PubMed ID: 18590816
[TBL] [Abstract][Full Text] [Related]
27. Anti-plasticizing effect of amorphous indomethacin induced by specific intermolecular interactions with PVA copolymer.
Ueda H; Aikawa S; Kashima Y; Kikuchi J; Ida Y; Tanino T; Kadota K; Tozuka Y
J Pharm Sci; 2014 Sep; 103(9):2829-2838. PubMed ID: 24890320
[TBL] [Abstract][Full Text] [Related]
28. Using the low-frequency Raman spectroscopy to analyze the crystallization of amorphous indomethacin.
Hédoux A; Paccou L; Guinet Y; Willart JF; Descamps M
Eur J Pharm Sci; 2009 Sep; 38(2):156-64. PubMed ID: 19591926
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of surface crystallisation of amorphous indomethacin particles in physical drug-polymer mixtures.
Priemel PA; Laitinen R; Barthold S; Grohganz H; Lehto VP; Rades T; Strachan CJ
Int J Pharm; 2013 Nov; 456(2):301-6. PubMed ID: 24012867
[TBL] [Abstract][Full Text] [Related]
30. Molecular dynamics simulation of amorphous indomethacin.
Xiang TX; Anderson BD
Mol Pharm; 2013 Jan; 10(1):102-14. PubMed ID: 23116319
[TBL] [Abstract][Full Text] [Related]
31. Nondestructive Investigation of the Agglomeration Process for Nanosuspensions via NMR Relaxation of Water Molecules.
Okada K; Hayashi Y; Kumada S; Onuki Y
Eur J Pharm Sci; 2021 Sep; 164():105908. PubMed ID: 34118410
[TBL] [Abstract][Full Text] [Related]
32. Effect of different preparation methods on the dissolution behaviour of amorphous indomethacin.
Karmwar P; Graeser K; Gordon KC; Strachan CJ; Rades T
Eur J Pharm Biopharm; 2012 Feb; 80(2):459-64. PubMed ID: 22019529
[TBL] [Abstract][Full Text] [Related]
33. T
Okada K; Hirai D; Hayashi Y; Kumada S; Kosugi A; Onuki Y
Chem Pharm Bull (Tokyo); 2019; 67(6):580-586. PubMed ID: 31155564
[TBL] [Abstract][Full Text] [Related]
34. Universal wet-milling technique to prepare oral nanosuspension focused on discovery and preclinical animal studies - Development of particle design method.
Niwa T; Miura S; Danjo K
Int J Pharm; 2011 Feb; 405(1-2):218-27. PubMed ID: 21167922
[TBL] [Abstract][Full Text] [Related]
35. The effect of low concentrations of molecularly dispersed poly(vinylpyrrolidone) on indomethacin crystallization from the amorphous state.
Crowley KJ; Zografi G
Pharm Res; 2003 Sep; 20(9):1417-22. PubMed ID: 14567636
[TBL] [Abstract][Full Text] [Related]
36. Composition-dependent structural changes and antitumor activity of ASC-DP/DSPE-PEG nanoparticles.
Higashi K; Mibu F; Saito K; Limwikrant W; Yamamoto K; Moribe K
Eur J Pharm Sci; 2017 Mar; 99():24-31. PubMed ID: 27916697
[TBL] [Abstract][Full Text] [Related]
37. Interaction studies between indomethacin nanocrystals and PEO/PPO copolymer stabilizers.
Liu P; Viitala T; Kartal-Hodzic A; Liang H; Laaksonen T; Hirvonen J; Peltonen L
Pharm Res; 2015 Feb; 32(2):628-39. PubMed ID: 25145336
[TBL] [Abstract][Full Text] [Related]
38. Screening for differences in the amorphous state of indomethacin using multivariate visualization.
Savolainen M; Heinz A; Strachan C; Gordon KC; Yliruusi J; Rades T; Sandler N
Eur J Pharm Sci; 2007 Feb; 30(2):113-23. PubMed ID: 17169536
[TBL] [Abstract][Full Text] [Related]
39. Identifying the correlation between drug/stabilizer properties and critical quality attributes (CQAs) of nanosuspension formulation prepared by wet media milling technology.
George M; Ghosh I
Eur J Pharm Sci; 2013 Jan; 48(1-2):142-52. PubMed ID: 23085547
[TBL] [Abstract][Full Text] [Related]
40. Wet milling induced physical and chemical instabilities of naproxen nano-crystalline suspensions.
Kumar S; Burgess DJ
Int J Pharm; 2014 May; 466(1-2):223-32. PubMed ID: 24614581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
